Nima Farzan's most recent trade in Keros Therapeutics Inc was a trade of 10,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Keros Therapeutics Inc | Nima Farzan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 10,500 | 10,500 | - | - | Stock Option (right to buy) | |
| Keros Therapeutics Inc | Nima Farzan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 5,250 | 5,250 | - | 0 | Common Stock | |
| Keros Therapeutics Inc | Nima Farzan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Keros Therapeutics Inc | Nima Farzan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Kinnate Biopharma Inc | Nima Farzan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 750,000 | 750,000 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Nima Farzan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 8,293 | 8,293 | - | - | Stock Options (right to buy) | |
| Kinnate Biopharma Inc | Nima Farzan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 400,000 | 400,000 | - | - | Employee Stock Option (right to buy) | |
| Keros Therapeutics Inc | Nima Farzan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 8,293 | 8,293 | - | - | Stock Option (right to buy) | |
| Kinnate Biopharma Inc | Nima Farzan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 275,000 | 275,000 | - | - | Employee stock option (right to buy) |